Jazz Pharmaceuticals (JAZZ) Earning Somewhat Favorable Press Coverage, Accern Reports

News headlines about Jazz Pharmaceuticals (NASDAQ:JAZZ) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 47.6784776523894 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern’s rankings:

Get Jazz Pharmaceuticals alerts:

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sle… (advfn.com) Jazz Pharmaceuticals (JAZZ) Given a $194.00 Price Target at Royal Bank of Canada (americanbankingnews.com) Analyzing Jazz Pharmaceuticals (JAZZ) & Celyad (CYAD) (americanbankingnews.com) Global Marine Pharmaceuticals Market Growing at a CAGR of 7.28% to 2022 (empowerednews.net) Physicians Unaware of Neurologic Effects Related to Obstructive Sleep Apnea, Finds Jazz Pharmaceuticals Survey (sleepreviewmag.com)

Shares of Jazz Pharmaceuticals traded up $1.75, hitting $170.75, during trading on Friday, MarketBeat reports. 928,650 shares of the company were exchanged, compared to its average volume of 466,308. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 0.87 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $171.76. The company has a quick ratio of 2.88, a current ratio of 3.00 and a debt-to-equity ratio of 0.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $2.98 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.78 by $0.20. The firm had revenue of $444.61 million for the quarter, compared to analyst estimates of $435.69 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The business’s quarterly revenue was up 18.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.31 EPS. analysts anticipate that Jazz Pharmaceuticals will post 11.65 earnings per share for the current year.

Several equities research analysts have commented on JAZZ shares. Bank of America boosted their target price on Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. BMO Capital Markets boosted their target price on Jazz Pharmaceuticals from $196.00 to $199.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Piper Jaffray Companies restated a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. BidaskClub upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 13th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $128.58 to $163.75 in a research note on Monday, March 19th. Five investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $182.49.

In related news, SVP Karen J. Wilson sold 3,899 shares of the business’s stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $155.00, for a total transaction of $604,345.00. Following the transaction, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Karen J. Wilson sold 3,760 shares of the business’s stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $165.00, for a total value of $620,400.00. Following the transaction, the senior vice president now directly owns 15,811 shares in the company, valued at $2,608,815. The disclosure for this sale can be found here. Insiders have sold a total of 15,825 shares of company stock worth $2,467,865 over the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Leave a Reply

Your email address will not be published. Required fields are marked *